# Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

> **NCT06393751** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Platinum-Refractory Fallopian Tube Carcinoma
- Platinum-Refractory Ovarian Carcinoma
- Platinum-Refractory Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube Adenocarcinoma
- Recurrent Fallopian Tube Carcinosarcoma
- Recurrent Fallopian Tube Clear Cell Adenocarcinoma
- Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
- Recurrent Fallopian Tube Undifferentiated Carcinoma
- Recurrent High Grade Endometrioid Adenocarcinoma
- Recurrent Ovarian Adenocarcinoma
- Recurrent Ovarian Carcinosarcoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Recurrent Ovarian Seromucinous Carcinoma
- Recurrent Ovarian Undifferentiated Carcinoma
- Recurrent Platinum-Resistant Fallopian Tube Carcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Adenocarcinoma
- Recurrent Primary Peritoneal Carcinosarcoma
- Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
- Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Primary Peritoneal Undifferentiated Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Paclitaxel
- **DRUG:** Tolinapant

## Key facts

- **NCT ID:** NCT06393751
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-10-31
- **Primary completion:** 2028-02-09
- **Final completion:** 2028-02-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Other - Protocol moved to Withdrawn
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393751, "Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06393751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*